Clear-cell Renal Cell Carcinoma - A Comprehensive Review of Agents Used in the Contemporary Management of Advanced/metastatic Disease

Overview

Journal Oncol Rev

Specialty Oncology

Date 2021 Mar 22

PMID 33747368

Citations 8

Authors

Stavros Gkolfinopoulos

Amanda Psyrri

Aristotelis Bamias

Affiliations

Soon will be listed here.

Abstract

Renal cell carcinoma represents the most common malignancy of the kidney and the majority of cases are categorized as clear cell carcinomas. The elucidation of the specific alterations in key molecular and metabolic pathways responsible for cancer development and progression have prompted the rationalization of our classification of this disease and have provided specific targetable molecules implicated in carcinogenesis. Although immunotherapy has been an established option in the treatment of metastatic renal cell cancer for many years, its role has been renewed and upgraded with the implementation of anti-angiogenic agents and immune checkpoint inhibitors in our treatment armamentarium. The future holds promise, as newer agents become available and combination regimens of immunotherapy with anti-angiogenic agents have become the standard of care in the management of metastatic disease and are currently being evaluated in earlier settings. Proper patient selection and individualization of our treatment strategies are of utmost importance in order to provide optimal care to patients suffering from renal cell carcinoma.

Citing Articles

Orbital metastasis of renal cell carcinoma masquerading as thyroid ophthalmopathy.

Aravind S, Sivasubramanian D, Sanil S, Prasaanth S, Senthilkumar V Radiol Case Rep. 2025; 20(4):1812-1815.

PMID: 39897743 PMC: 11783215. DOI: 10.1016/j.radcr.2024.12.052.

Retrospective study assessing the role of the androgen receptor in clear cell renal cell cancer patients treated with VEGFR inhibitors in monotherapy.

Osorio L, Grazioso T, de Velasco G, Etxaniz O, Perez-Gracia J, Pinto A Clin Transl Oncol. 2024; .

PMID: 39365364 DOI: 10.1007/s12094-024-03652-9.

Combined Clear Cell Renal Cell Carcinoma and Chromophobe Renal Cell Carcinoma: A Case Report.

Meliti A, Alardati H, Khayat M, Alruqi A Cureus. 2024; 16(6):e61940.

PMID: 38978897 PMC: 11230612. DOI: 10.7759/cureus.61940.

Iris metastasis from clear cell renal cell carcinoma: A case report.

Wang T, Chen X, Min Q, Han Y, Zhao H World J Clin Cases. 2024; 11(36):8535-8541.

PMID: 38188215 PMC: 10768508. DOI: 10.12998/wjcc.v11.i36.8535.

The Role of CT Imaging in Characterization of Small Renal Masses.

Bazzocchi M, Zilioli C, Gallone V, Commisso C, Bertolotti L, Pagnini F Diagnostics (Basel). 2023; 13(3).

PMID: 36766439 PMC: 9914376. DOI: 10.3390/diagnostics13030334.

References

Choueiri T, Pal S, McDermott D, Morrissey S, Ferguson K, Holland J . A phase I study of cabozantinib (XL184) in patients with renal cell cancer. Ann Oncol. 2014; 25(8):1603-8. PMC: 6279111. DOI: 10.1093/annonc/mdu184. View

Sternberg C, Davis I, Mardiak J, Szczylik C, Lee E, Wagstaff J . Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010; 28(6):1061-8. DOI: 10.1200/JCO.2009.23.9764. View

Choueiri T, Hessel C, Halabi S, Sanford B, Michaelson M, Hahn O . Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update. Eur J Cancer. 2018; 94:115-125. PMC: 6057479. DOI: 10.1016/j.ejca.2018.02.012. View

Rini B, Plimack E, Stus V, Gafanov R, Hawkins R, Nosov D . Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 2019; 380(12):1116-1127. DOI: 10.1056/NEJMoa1816714. View

Dudkin L, Dilling M, Cheshire P, Harwood F, Hollingshead M, Arbuck S . Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition. Clin Cancer Res. 2001; 7(6):1758-64. View

Kumar R, Knick V, Rudolph S, Johnson J, Crosby R, Crouthamel M . Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther. 2007; 6(7):2012-21. DOI: 10.1158/1535-7163.MCT-07-0193. View

Shah A, Kotecha R, Lemke E, Chandramohan A, Chaim J, Msaouel P . Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors. Eur J Cancer. 2019; 114:67-75. PMC: 7537491. DOI: 10.1016/j.ejca.2019.04.003. View

Xu R, Wang K, Rizzi J, Huang H, Grina J, Schlachter S . 3-[(1,2,3)-2,3-Difluoro-1-hydroxy-7-methylsulfonylindan-4-yl]oxy-5-fluorobenzonitrile (PT2977), a Hypoxia-Inducible Factor 2α (HIF-2α) Inhibitor for the Treatment of Clear Cell Renal Cell Carcinoma. J Med Chem. 2019; 62(15):6876-6893. DOI: 10.1021/acs.jmedchem.9b00719. View

Motzer R, Penkov K, Haanen J, Rini B, Albiges L, Campbell M . Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 2019; 380(12):1103-1115. PMC: 6716603. DOI: 10.1056/NEJMoa1816047. View

10.

Motzer R, Rini B, Bukowski R, Curti B, George D, Hudes G . Sunitinib in patients with metastatic renal cell carcinoma. JAMA. 2006; 295(21):2516-24. DOI: 10.1001/jama.295.21.2516. View

11.

Escudier B, Eisen T, Stadler W, Szczylik C, Oudard S, Staehler M . Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol. 2009; 27(20):3312-8. DOI: 10.1200/JCO.2008.19.5511. View

12.

Motzer R, Hutson T, Glen H, Michaelson M, Molina A, Eisen T . Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol. 2015; 16(15):1473-1482. DOI: 10.1016/S1470-2045(15)00290-9. View

13.

Hutson T, Escudier B, Esteban E, Bjarnason G, Lim H, Pittman K . Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2013; 32(8):760-7. PMC: 5569683. DOI: 10.1200/JCO.2013.50.3961. View

14.

Motzer R, Escudier B, Mcdermott D, George S, Hammers H, Srinivas S . Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015; 373(19):1803-13. PMC: 5719487. DOI: 10.1056/NEJMoa1510665. View

15.

Motzer R, Hutson T, Cella D, Reeves J, Hawkins R, Guo J . Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013; 369(8):722-31. DOI: 10.1056/NEJMoa1303989. View

16.

Schmidt A, Siefker-Radtke A, McConkey D, McGregor B . Renal Cell and Urothelial Carcinoma: Biomarkers for New Treatments. Am Soc Clin Oncol Educ Book. 2020; 40:1-11. DOI: 10.1200/EDBK_279905. View

17.

Hutson T, Lesovoy V, Al-Shukri S, Stus V, Lipatov O, Bair A . Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial. Lancet Oncol. 2013; 14(13):1287-94. DOI: 10.1016/S1470-2045(13)70465-0. View

18.

Shah N, Kelly W, Liu S, Choquette K, Spira A . Product review on the Anti-PD-L1 antibody atezolizumab. Hum Vaccin Immunother. 2017; 14(2):269-276. PMC: 5806639. DOI: 10.1080/21645515.2017.1403694. View

19.

Jager D, Ma J, Mardiak J, Ye D, Korbenfeld E, Zemanova M . Sorafenib treatment of advanced renal cell carcinoma patients in daily practice: the large international PREDICT study. Clin Genitourin Cancer. 2014; 13(2):156-64.e1. DOI: 10.1016/j.clgc.2014.07.007. View

20.

Siegel R, Miller K, Jemal A . Cancer statistics, 2020. CA Cancer J Clin. 2020; 70(1):7-30. DOI: 10.3322/caac.21590. View